Search

The history of the vole type of tubercle bacillus and of the Medical Research Council's trial of vole bacillus vaccine in 1950 is summarized. Fifteen years after this trial 110 vaccinated subjects were re-examined. Seventeen were found to have granulomatous lesions at the vaccination site. The clinical and histological features of the lesions are described. No bacteria could be demonstrated in the lesions histologically or by inoculation of voles. The lesions responded to the administration of antituberculous drugs. The term lupus murinus is proposed for the dermatological lesion induced by primary inoculation with live Mycobacterium tuberculosis var. muris. [ABSTRACT FROM AUTHOR]

Four patients with advanced mycosis fungoides presenting at the tumour stage were selected for treatment with the combination of cyclophosphamide and chlorpromazine. Cyclophosphamide was given alone initially and in 3 of the patients remissions occurred which lasted between 5 to 8 months. The fourth, Case 4, did not respond to cyclophosphamide alone. In all 4 patients when cyclophosphamide was given with chlorpromazine, longer remissions, lasting 3 to 18 months, occurred. It seems from this series that tumour growth is inhibited when chlorpromazine and cyclophosphamide are administered together, and that the combination of the 2 drugs produces longer remissions than cyclophosphamide alone. [ABSTRACT FROM AUTHOR]

Five patients with chronic discoid lupus erythematosus who had never received antimalarial drugs were given amodiaquine and serial electro-oculograms (E.O.G.s) recorded. In four of the five there was a significant drop in the E.O.G. values within a month of starting treatment, with complete return to normal values within two months of stopping the drug. No visual symptoms or ophthalmoscopic abnormality were noted during the period of the investigation. [ABSTRACT FROM AUTHOR]

The article presents information on a trial of amopyroquin in the treatment of chronic discoid lupus erythematosus. In this trial the dosage was 150 mg. per diem, the minimum recommended. All of the sixteen patients had chronic discoid lupus erythematosus for periods varying from 6 months to 23 years. Each had received either one or more antimalarial drugs in the past. Each patient was seen once weekly at the outset, and then every two weeks throughout the remainder of the trial. Prior to treatment in the trial a medical history was taken and a general examination was made.